NCT03250598已完成1 期
A Phase 1, Single-Dose, Open-Label Study to Characterize and Compare the Pharmacokinetics, Safety, and Effect on QTc Interval of AG-348 in Healthy Subjects of Japanese Origin and Healthy Subjects of Non-Asian Origin
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- AUC
研究概览
简要总结
The purpose of this Phase I, single-dose, open-label trial is to evaluate the pharmacokinetics, safety, and effect on QTc interval of AG-348 in healthy, adult Japanese and Non-Asian subjects. The study plans to evaluate 3 cohorts of a single oral dose of AG-348 in Japanese and Non-Asian subjects. Pharmacokinetic sampling will take place serially at specified times during conduct of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Be a male or female aged 18 to 55 years, inclusive.
- •Have a body mass index (BMI) of ≥ 18.5 to ≤ 29.0 kg/m2 at Screening.
- •Be healthy overall with no clinically significant medical abnormalities, as determined by the Investigator through evaluation of the subject's medical history and Screening vital signs, ECG, physical examination, and laboratory assessments.
- •Applicable to Japanese Subjects Only: Japanese subjects must have been born in Japan, have both parents and all grandparents of Japanese origin, and not have lived outside of Japan for more than 5 years with no significant changes in lifestyle, including diet, since leaving Japan.
- •Applicable to Non-Asian Subjects Only: Non-Asian subjects must have both parents and all grandparents of Non-Asian origin.
排除标准
- •Have undergone any major surgical procedure within the 3 months prior to Screening.
- •Test positive at Screening for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCVAb), or human immunodeficiency virus (HIV).
- •Have a Screening systolic blood pressure (BP) reading of > 140 mmHg (> 150 mmHg in subjects > 45 years of age) OR a diastolic BP reading of > 90 mmHg after 5 minutes of supine rest.
- •Have any of the following cardiac risk factors:
- •Be taking any medication with a known effect of QT interval prolongation (see list of medications in Appendix 1)
- •Have a cardiac pacemaker
- •Demonstrate on either the Screening ECG or the baseline ECG any evidence of atrial fibrillation, atrial flutter, complete right or left bundle branch block, or Wolff-Parkinson-White syndrome
- •Demonstrate on the Screening ECG any morphology that renders measurement of QT interval imprecise (eg, neuromuscular artifact that cannot be readily eliminated, indistinct QRS onset, low-amplitude T wave, merged T and U waves, prominent U waves, arrhythmia)
- •Have a history of a known risk factor for Torsade de Pointes, including any of the following:
- •Personal or family history of congenital long QT syndrome, Brugada syndrome, or sudden death
- •Unexplained syncope
- •Heart failure
- •Myocardial infarction
- •Certain clinically significant laboratory assessment findings, including hypokalemia, hypercalcemia, or hypomagnesemia
- •Have had, including by voluntary donation, > 400 mL of blood collected within the 3 months prior to Screening.
- •Have taken within the 14 days prior to study drug dosing any prescription medication, over-the counter medication, or nonprescription preparation-including vitamins, minerals, phytotherapeutic/herbal/plant-derived preparations, or grapefruit juice-unless deemed acceptable by the Investigator OR have taken within the 28 days prior to study drug dosing any restricted product known to strongly induce CYP3A4 metabolism (eg, St. John's Wort).
- •Have participated in another clinical research study within the 3 months prior to Screening.
研究组 & 干预措施
Cohort A
Experimental
干预措施: AG-348 (Drug)
Cohort B
Experimental
干预措施: AG-348 (Drug)
Cohort C
Experimental
干预措施: AG-348 (Drug)
结局指标
主要结局
AUC
时间窗: Pharmacokinetic sampling for AG-348 will be taken for 72 hours (4 days) after single dose
AG-348 Area Under the Curve
Cmax
时间窗: Pharmacokinetic sampling for AG-348 will be taken for 72 hours (4 days) after single dose
AG-348 Maximum Plasma Concentration
次要结局
- Incidence of Adverse Events(10 (± 1) days after single-dose of AG-348)
- QTc interval(Change in QTc from baseline will be presented by race and by cohort)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Japanese Bridging Study of Ivosidenib (AG-120) in Healthy SubjectsHealthyNCT03071770Agios Pharmaceuticals, Inc.60
已完成
1 期
A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic FunctionHepatic ImpairmentNCT01631097AVEO Pharmaceuticals, Inc.44
已完成
1 期
Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532HealthyType 2 Diabetes MellitusNCT01369602Pfizer27
已完成
1 期
Desidustat in the Treatment of Chemotherapy Induced AnemiaAnemia of Chronic Kidney DiseaseChemotherapy EffectNCT04667533Zydus Lifesciences Limited24
已完成
1 期
Evaluate the Pharmacokinetics and Safety of EXPAREL® Following Subcutaneous Administration in Healthy Chinese SubjectsHealthy SubjectsNCT04158102Nuance Pharma (shanghai) Co., Ltd20